Vivo Capital, LLC Trevi Therapeutics, Inc. Transaction History
Vivo Capital, LLC
- $512 Million
- Q4 2024
A detailed history of Vivo Capital, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Vivo Capital, LLC holds 3,487,903 shares of TRVI stock, worth $15.8 Million. This represents 2.9% of its overall portfolio holdings.
Number of Shares
3,487,903
Previous 1,612,903
116.25%
Holding current value
$15.8 Million
Previous $5.39 Million
175.81%
% of portfolio
2.9%
Previous 0.79%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
114Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$51.4 Million3.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.7MShares$48.2 Million2.72% of portfolio
-
Viking Global Investors LP4.4MShares$19.9 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$19 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$18.8 Million0.04% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $264M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...